The tumor suppressor p53 transcriptionally transactivates cellular target genes that are implicated in growth control, apoptosis, and DNA repair. However, several studies involving p53 core domain mutants suggested that regulatory functions in recombinative repair do not require transcriptional transactivation and are separable from growth-regulation and apoptosis. Leu22 and Trp23 within the transactivation domain of human p53 play a critical role in binding basal components of the transcription machinery and, therefore, in the transactivation activity of p53. To further delineate whether p53 target genes are involved in recombination regulation, we ectopically expressed p53(22Q,23S) in p53-negative cell lines, which carry reporter systems for different homology-directed double-strand break (DSB) repair events. Like wild-type p53, p53(22Q,23S) efficiently downregulated homologous recombination on two chromosomally integrated substrates without affecting exchange on a substrate for the compound pathway of gene conversion and nonhomologous end joining. Only upon lowering the p53 protein to DNA substrate ratio by several orders of magnitude, we noticed a weak defect of a p53 transactivation domain mutant in DSB repair assays. In conclusion, molecular interactions of p53 within the N-terminal domain are not required to restrain DNA recombination, but might contribute to this genome stabilizing function.
The tumor suppressor p53 transcriptionally transactivates cellular target genes that are implicated in growth control, apoptosis, and DNA repair. However, several studies involving p53 core domain mutants suggested that regulatory functions in recombinative repair do not require transcriptional transactivation and are separable from growth-regulation and apoptosis. Leu22 and Trp23 within the transactivation domain of human p53 play a critical role in binding basal components of the transcription machinery and, therefore, in the transactivation activity of p53. To further delineate whether p53 target genes are involved in recombination regulation, we ectopically expressed p53(22Q,23S) in p53-negative cell lines, which carry reporter systems for different homology-directed double-strand break (DSB) repair events. Like wild-type p53, p53(22Q,23S) efficiently downregulated homologous recombination on two chromosomally integrated substrates without affecting exchange on a substrate for the compound pathway of gene conversion and nonhomologous end joining. Only upon lowering the p53 protein to DNA substrate ratio by several orders of magnitude, we noticed a weak defect of a p53 transactivation domain mutant in DSB repair assays. In conclusion, molecular interactions of p53 within the N-terminal domain are not required to restrain DNA recombination, but might contribute to this genome stabilizing function. Oncogene (2003 Oncogene ( ) 22, 4111-4117. doi:10.1038 Keywords: genome stability; homologous recombination; p53; transcriptional transactivation; tumor suppression Several different biological functions of wild-type p53 (wtp53) have been linked to the maintenance of genome stability (Levine, 1997; Albrechtsen et al., 1999; Morris, 2002 ). The initial model described p53 as a transcription factor, which becomes activated in response to DNA damage, and subsequently activates the G1 checkpoint, to allow DNA repair before replication. Cell cycle arrest is induced by transactivation of the WAF1/CIP1/p21 promoter. Additionally, other transcriptional target genes of p53 have been discovered, which mediate p53 functions in damage-induced apoptosis, that is, in the elimination of severely damaged cells. Yet until today, there is some controversy as to whether p53 may additionally induce apoptosis by a transcription-independent pathway (Haupt et al., 1995; Theis et al., 1997; Cain et al., 2000; Jimenez et al., 2000; Kokontis et al., 2001; Matas et al., 2001; Moll and Zaika, 2001 ). The experimental design of these studies relied on the identification of a domain within the N-terminal 42 amino acids of human p53, which interact with the hTAF II 31 and 70 coactivator proteins of the basal transcription machinery (Lu and . p53 mutated at amino acids 22 and 23 [p53(22,23) ] within this transactivation domain was frequently employed to demonstrate that p53-dependent apoptosis was compromised or completely abolished, and served to identify a proline-rich domain that contributes to apoptosis induction (Haupt et al., 1995; Sabbatini et al., 1995) . Mutation at residues 22 and 23 also renders p53 unable to bind HDM2, a major negative regulator of p53 function, which conceals the transactivation domain of p53 and which targets p53 for degradation in the proteasome (Lin et al., 1994) .
Other genome stabilizing functions of p53 have been proposed, namely a stimulatory involvement in nucleotide and base-excision repair, and the inhibition of errorprone DNA recombination (Albrechtsen et al., 1999; McKay et al., 1999; Offer et al., 1999) . As with cell cycle control and apoptosis induction, transcriptional transactivation seems to underly some of these DNA repairrelated functions. Thus, p53 induces the p48 xeroderma pigmentosum gene, which is participating in global genomic nucleotide excision repair (McKay et al., 1999) . On the other hand, accumulating evidence indicates that p53 mediates DNA repair by additional transcriptionindependent routes. With respect to nucleotide excision repair, functional interactions between p53 and the helicase subunits of the dual transcription/nucleotide excision repair complex TFIIH and with the Cockayne syndrome complementation group B protein have been described. Most recently, p53 was also shown to stimulate base-excision repair (Offer et al., 1999) , possibly via direct interactions with polymerase b (Zhou et al., 2001) . From the molecular interactions and enzymatic activities of p53, several mechanisms underlying a direct regulation of homologous recombination have been discussed. First, p53 may act antirecombinogenic by modulating the functions of BLM, a RecQ DNA helicase, which disrupts potentially recombinogenic molecules that arise at sites of defective processing of DNA replication intermediates (Wang et al., 2001) . Second, p53 may block continued strand exchange by the recombinase RAD51, when binding to nascent intermediates of homologous recombination (Stu¨rzbe-cher et al., 1996; Su¨sse et al., 2000) . Third, exonucleolytic proofreading of mispaired heteroduplexes may dissolve recombination junctions (Su¨sse et al., 2000; Janz et al., 2002) .
Previously, we and others provided evidence for a transactivation independent role of p53 in regulating recombinative repair (Dudenho¨ffer et al., 1999; Saintigny et al., 1999; Willers et al., 2000; Akyu¨z et al., 2002) . However, these results were based on experimental data obtained with central core domain mutants, which may retain transcriptional transactivation for certain groups of target genes or may even gain functions in recognizing new promoters (Roemer, 1999; Campomenosi et al., 2001) . In this study, we attempted to unequivocally decide, whether transactivation is involved in restraining the exchange of homologous sequences by use of p53 mutated in the transactivation domain.
Analysis of homology-directed double-strand break repair DNA double-strand breaks (DSBs) are the principal cytotoxic lesions that appear in response to ionizing radiation and when a replicative DNA polymerase encounters a single-strand break or another type of lesion (Flores-Rozas and Kolodner, 2000; Khanna and Jackson, 2001 ). There are two major pathways of DSB repair, nonhomologous end-joining (NHEJ) and homologous recombination. The latter is further subgrouped into conservative and nonconservative events, depending on whether homologous sequences are copied in such a way that the damaged acceptor copy is fully reconstituted by the donor template or whether the repair is accompanied by the loss of DNA sequences between the homologous sequences (see Figure 1) . Recently, we generated a test system, which permits to characterize the regulatory potential of p53 in the different pathways of DSB repair (Akyu¨z et al., 2002) . The assay is designed in such a way that recombinative DNA-exchange processes involving differentially mutated EGFP genes reactivate the intense autofluorescence of EGFP. Thus, Figure 1 Recombination substrates. Test cell lines derived from K562 carry EGFP-based recombination substrates and were established after electroporation with vector D-EGFP/3 0 EGFP, HR-EGFP/3 0 EGFP, and EJ-EGFP/3 0 EGFP, respectively, followed by soft-agar cloning and puromycin selection (Akyu¨z et al., 2002) . All the recombination plasmids contain the following elements in series: a puromycin resistance gene, an acceptor EGFP gene following a CMV promoter and containing a cleavage site (black triangle) for the rare-cutting I-SceI meganuclease, a 2 kb spacer sequence, and the donor 3 0 EGFP gene which carries truncating stop codons in place of the start codon (black cross). Among the three acceptor genes D-EGFP was devoid of 46 bp and HR-EGFP of 4 bp from EGFP adjacent to the I-SceI cleavage site. In EJ-EGFP, the ISceI site was inserted between a 5 bp duplication, to support microhomology-mediated NHEJ. Expression of I-SceI results in a DSB targeted to the acceptor EGFP gene (scissors). Both conservative and nonconservative recombination between the differentially mutated EGFP genes restore a functional EGFP gene at the acceptor position. Therefore, the EGFP reactivation frequency is determined from the fraction of green fluorescent cells within a population of nonfluorescent cells (Rouet et al., 1994) . Expression of the meganuclease in cells that have the EGFP reporter substrates integrated into the genome results in DSBs in the chromosome at the positions of the I-SceI sites. Incorporation of D-or HR-EGFP at the upstream acceptor position supports homologous recombination involving short and long stretches of homologies. EJ-EGFP participates in the pathway that couples gene conversion and NHEJ (Richardson and Jasin, 2000; Akyu¨z et al., 2002) . The 5 0 truncated 3 0 EGFP gene at the downstream donor position serves as a recombination substrate for both conservative and nonconservative events. Thus, by use of this system all homologous recombination pathways, known so far, can be analysed.
p53(22Q,23S) downregulates homologous recombination
Since p53 mutants with amino-acid exchanges at positions 22 and 23 have proven to be an extremely useful tool for studying the relevance of transactivation functions, we have applied our EGFP-based recombination test system to the analysis of p53(22,23). To study homology-directed DSB repair on cellular chromosomes, we utilized KMV cell clones, originating from the p53-negative, human erythroleukemia cell line K562, with stably integrated D-EGFP/3 0 EGFP, HR-EGFP/3 0 EGFP, or EJ-EGFP/3 0 EGFP substrate (Akyu¨z et al., 2002) . Without genotoxic treatment of the cells, spontaneous recombination was rare, because the fraction of EGFP-positive cells was o10 À4 in any of the cell clones (data not shown). To express the I-SceI meganuclease for targeted DSB formation, we electroporated our tester strains with the I-SceI expression plasmid pCMV-I-SceI (Rouet et al., 1994) . After 72 h of further incubation the cells were examined flow-cytometrically (Figure 2a, b) . The fraction of EGFP-positive cells was normalized for the individual transfection , HR-EGFP/3 0 EGFP: 14.1 Â 10 À4 , and EJ-EGFP/3 0 EGFP: 6.7 Â 10 À4 ). To modify the p53 status, we introduced either pCMV-wtp53, pCMV-p53(22Q,23S), pCMVp53(273 H), or the control vector pCMV-pA together with pCMV-I-SceI. pCMV-wtp53-transfected cells exhibited many fewer EGFP-positive cells, such that there was a fourfold decrease in D-EGFP/3 0 EGFP-cells and a fivefold decrease in HR-EGFP/3 0 EGFP-cells relative to the same cells after transfection with the backbonevector (Figure 2a, b) . In contrast, unchanged recombination frequencies were measured upon expression of the cancer-related mutant p53(273 H) in both tester strains. When we expressed the transactivation domain mutant p53(22Q,23S) (Figure 2c ), we scored eight-and fivefold reduced frequencies, without significant differences from the mean values obtained for wtp53. Previously, we noticed that wtp53 shows little or no influence on DNA exchange processes involving substrates for both homologous recombination and microhomology-mediated NHEJ (Akyu¨z et al., 2002) . Accordingly, none of the p53 variants affected DSB repair in the cells carrying the EJ-EGFP/3 0 EGFP substrate. The latter result concomitantly excluded the possibility that apoptosis induction by wtp53 or p53(22Q,23S) indirectly caused recombination frequency changes in D-EGFP/3 0 EGFP-and HR-EGFP/ 3 0 EGFP-cells in response to I-SceI-mediated DSB formation. Additionally, for our studies we had chosen the human myeloid leukemia cell line K562, since it does not undergo apoptosis, when wtp53 is expressed (Mahdi et al., 1998) . To further exclude rate deviations related to growth regulatory effects or apoptosis induction, the fraction of EGFP-positive cells after electroporation with a wild-type EGFP control plasmid was determined in parallel to each single recombination experiment, that is, after I-SceI expression together with or without p53, and was used to normalize the recombination frequencies.
Influence of the p53/DNA substrate ratio on the recombination frequency Previously, we and others noticed differences in the degree of recombination interference by p53, when the DNA substrates were presented extrachromosomally in high copy numbers rather than on the chromosome in very few copies, and when the protein expression level was significantly reduced (Willers et al., 2001; Akyu¨z et al., 2002) . Therefore, we chose to introduce the corresponding changes during recombination measurements, to ask whether transactivation domain mutants of p53 display subtle defects in restraining DNA exchange. For this purpose, we raised the number of recombination substrate molecules by transient transfection and expressed p53 at a low expression level with the pSV53her vector. This SV40 promoterdriven expression construct induces the production of approximately 100-fold lower protein amounts as compared to the pCMV-vector (Figure 3c ). pSV53her directs the expression of p53her, that is, human wtp53 fused to the human estrogen receptor hormone-binding domain, and has been successfully applied to functional studies of p53 before (Roemer and Friedman, 1993; Dudenho¨ffer et al., 1998) . The introduction of numerous copies of D-EGFP/3 0 EGFP plasmid into KMV cells raised the DSB repair frequency from 7 Â 10 À4 to 9 Â 10 À2 (Figure 2a versus 3a) . Here, I-SceI meganuclease production relied on the estradiol-responsive expression cassette located on the extrachromosomal recombination plasmid (Akyu¨z et al., 2002) . Coelectroporations were performed with pSV53her, pSVp53(22E,23S)her, pSVp53(1-333)her, and pBS, respectively. Despite the relatively low p53/DNA substrate ratio in these experiments, we still noticed a wtp53-dependent recombination suppression by 40% (Figure 3a, b) . Upon the introduction of the p53(22E,23S) hybrid, homologous recombination between D-EGFP and 3 0 EGFP was reduced by 20%, whereas no reduction was observed with the Cterminally truncated p53(1-333) variant, which lacks the oligomerization domain (Dudenho¨ffer et al., 1999) .
Role of p53 transactivation domain in homologous recombination
In this work, we expressed human p53 proteins with exchanges of leucine 22 and tryptophan 23, wtp53, and p53 mutants with well-described recombination-regulatory defects (Dudenho¨ffer et al., 1999; Saintigny et al., 1999; Akyu¨z et al., 2002) in the same parental cell line and analysed homology-directed repair on chromosomal and extrachromosomal substrates. NMR structure analysis has shown that the peptide segment surrounding the two hydrophobic residues 22 and 23 no longer adopts a two-beta-turn, but displays a random structure upon replacement with glutamine and serine (Botuyan et al., 1997) . This explains why the association of p53 with coactivator proteins of the basal transcription machinery heavily depends on the integrity of these two amino acids, and why double point mutation renders p53 transcriptionally inactive (Lu and Levine, 1994) . In contrast, p53(22,23) was fully active in counteracting recombination between repeat substrates, independent of the homology length adjacent to the DSB (D-EGFP/ 3 0 EGFP versus HR-EGFP/3 0 EGFP). This recombination suppression was specific for homology-directed DSB repair, as it was lost with a construct supporting the genome-stabilizing pathway that couples NHEJ and gene conversion (EJ-EGFP/3 0 EGFP) (Richardson and Jasin, 2000; Akyu¨z et al., 2002) . Importantly also, this effect cannot be explained by unspecific molecular interactions due to protein overproduction, because p53(273 H) with wtp53 conformation did not alter the DSB repair frequencies. Taken together, with respect to recombination measured at chromosomal sites, p53(22,23) exhibited regulatory activities that were indistinguishable from the ones seen with wtp53. This suggests that the N-terminus of p53 is not essential for this repair-related activity. These conclusions are in agreement with our previous findings indicating recombination inhibition after coexpression of wtp53 and HDM2 (Dudenho¨ffer et al., 1999) . The data also correlate with the results from DNA-binding studies with N-terminally truncated p53 and artificial recombination intermediates.
Taken together, our data further strengthen the proposal that direct interactions with DNA intermediates and/or repair enzymes rather than transcriptional transactivation of a putative recombination-related p53 target gene are underlying its antirecombinogenic activity (Stu¨rzbecher et al., 1996; Su¨sse et al., 2000; Wang et al., 2001) . So far, support for this transactivation-independent involvement of p53 in homologous recombination processes came from the discovery of central core domain mutants with separable functions in transcriptional transactivation and recombination (Dudenho¨ffer et al., 1999; Saintigny et al., 1999; Willers et al., 2000; Akyu¨z et al., 2002) . However, in this study, we also noticed that the downregulatory effect of p53(22,23) was less pronounced after transient transfection with the recombination plasmid, that is, upon a dramatic rise in the copy number of I-SceI-cleaved substrate DNA. Under these conditions, intermediate activities of p53(22,23) in recombination were detected, which raises questions on the complementary involvement of a downstream target gene. For this, the best candidate seems to be MSH2, because a p53 response element was found in the promoter region of the human MSH2 gene (Scherer et al., 1996; Warnick et al., 2001) . MSH2, like p53, has been proposed to control the fidelity of homologous recombination by suppressing the exchange of divergent sequences (Modrich and Lahue, 1996; Dudenho¨ffer et al., 1998) . Additionally, MSH2 and MSH3 from yeast are involved in the removal of nonhomologous overhangs during the nonconservative pathway of single-strand annealing (Sugawara et al., 1997) . However, the accumulation of p53 in response to DNA damage is not followed by an increase of endogenous MSH2 levels, which argues against a p53-dependent upregulation of MSH2 (Zink et al., 2002) . Moreover, heterozygosity of p53 on a MSH2 negative background was demonstrated to promote microsatellite instability, indicating a fidelity control function of p53 independent of MSH2 (Toft et al., 2002) .
Interestingly, double mutation within the transactivation domain was also reported to weaken the molecular interactions of p53 with polymerase b and, concomitantly, to alleviate its stimulatory role in base-excision repair (Zhou et al., 2001) . Both polymerase a and b are missing proofreading functions, and the 3 0 -5 0 exonuclease of p53 has been shown to increase the fidelity of polymerase a (Mummenbrauer et al., 1996; Huang, Figure 3 Homologous recombination in cells expressing p53(22E,23S)her. (a) Recombination measurements. The KMV cells used here derive from the human myeloid leukemia cell line K562 and express the estradiol-inducible transcription factor GalERVP (Akyu¨z et al., 2002) . Recombination assays were performed by colelectroporating KMV cells with 10 mg of pSVp53her (wtp53), pSVp53(22E,23S)her, pSVp53(1-333)her, or pBS (control) and with 5 mg of recombination plasmid D-EGFP/3 0 EGFP containing a Gal-ERVP-responsive I-SceI expression cassette within the spacer region (Akyu¨z et al., 2002) . To induce I-SceI-mediated cleavage, estradiol was included into the growth medium at a final concentration of 200 nm. Recombination frequencies were calculated as the number of fluorescing cells divided by the total number of successfully transfected cells. The mean values and SEs of three to six recombination measurements are shown graphically. The pSV53her (Roemer and Friedman, 1993) derivative pSVp53(22E,23S)her was engineered by in vitro mutagenesis with oligonucleotide 5 0 -TTTTCAGGAAGTAGTTTCGATTGGTCT-GAAAAT GTTTCC-3 0 (mutating bases are underlined) and the USE mutagenesis kit from Pharmacia. The sequence of the complete coding region was verified by use of the ABi PRISM Big Dye Ready Reaction Cycle Sequencing kit and an ABi 377 sequencer. (b) Relative recombination frequencies. The recombination frequency in the control was taken as 100%. (c) Relative protein expression levels. Western blotting of total cellular homogenates was performed 72 h after electroporation with 0.01-10 mg of pCMV-wtp53 or with 10 mg of pSV53her, as described in Figure 2c . To compare p53 protein expression levels, we used mAb DO1 (Calbiochem) for immunodetection. The positions of p53 and p53her are marked p53(22,23) in homologous recombination GS Boehden et al 1998; Melle and Nasheuer, 2002) . In analogy, complex formation between polymerase b and p53 may reduce infidelities during polymerase b-dependent repair replication, such as during base-excision repair, NHEJ, and possibly also during homologous recombination (Plug et al., 1997; Reichenberger and Pfeiffer, 1998) . In yeast, base excision repair and recombination show overlapping specificities for the removal of certain types of DNA damage, as indicated by the hyper-recombinogenic phenotype after the disruption of base-excision repair genes (Doetsch et al., 2001) . Vice versa, cells without the DSB repair factor BRCA2 perform baseexcision repair at a reduced rate (Bogliolo et al., 2000) . Therefore, direct and indirect links between polymerase b and recombination seem to exist and may alternatively explain, why, with extrachromosomal substrates, we observed a minor defect in recombination downregulation by p53 (22, 23) . Finally, reduced dissociation from DNA was seen with p53 protein mutated within the N-terminus (Cain et al., 2000; Jimenez et al., 2000) . However, fast on-and off-rates were reported for p53-specific interactions with DNA recombination intermediates and reiterative binding is required for a homology scanning mechanism (Dudenho¨ffer et al., 1998) . Thus, p53(22,23) may also be slow in recognizing the sites of repair, especially, when these sites are present at a high concentration.
To analyse the tumor suppressor activities of transactivation-deficient p53 in vivo, two groups have generated knockin mouse models for p53(25Q,26S), the murine equivalent of p53(22Q, 23S) (Chao et al., 2000; Jimenez et al., 2000) . According to their data, p53(25Q,26S) had completely lost the capacity to induce apoptosis and the knockin mice frequently developed malignancies, stressing the importance of transactivation for tumor prevention. However, the lack of tumors in mice nullizygous for p21, in a fraction of mice transgenic for the transcriptionally inactive but recombination-regulatory mutant p53(135Val), and in mice treated with PFTa, a small molecule, which inhibits p53-dependent transactivation and apoptosis but not fidelity control of recombination, indicate that mechanisms alternative to transcriptional transactivation may contribute to tumor suppression by p53 (Deng et al., 1995; Schaffner et al., 1996; Komarov et al., 1999; Willers et al., 2000; Lin et al., 2003) .
Clearly, error-prone recombination increases the cancer risk, as is illustrated best by the large number of breast cancer susceptibility syndromes that are related to defects in recombination surveillance factors (Thompson and Schild, 2001) . Li-Fraumeni patients with an inherited defect in the p53 gene are characterized by a predominance of breast carcinomas (Soussi et al., 1993; Kuperwasser et al., 2000) . Conversely, transgenic mice harboring a mutant p53 gene develop mammary tumors rarely. Therefore, different modifier genes involved in cancer formation may be active in mice and human beings, and may also cause differences concerning the importance of single tumor-promoting activities of mutant p53. The results from our present study in combination with our latest mutant data suggest that the regulation of recombinative genome rearrangements by p53 may represent a role in cancer prevention that does not depend on the critical tumor suppressor function of target gene activation. Consequently, we propose that excess recombination activities due to mutations in the p53 gene underly the high rate of chromosomal aberrations associated with the Li-Fraumeni syndrome and contribute to the formation of early-onset neoplasms and multiple primary tumors.
